Obviously, additional ex vivo experiments conducted on larger series of CML patients and with the second- and third-generation TKIs are required to evaluate the potential usefulness of combining the BMI1 inhibitors with TKIs in resistant cases. The gene discussed is BMI1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.